Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Pfisterer

Showing results (41-50 of 87) with videos related to

Pageof 9
Sort By:
Journal of the American College of Cardiology|February 25, 2012
Coronary artery disease progression late after successful stent implantationMichael J Zellweger, Christoph Kaiser, Raban Jeger, et al.
European Journal of Heart Failure|March 16, 2017
Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)Peter Rickenbacher, Beat A Kaufmann, Micha T Maeder, et al.
Lancet (London, England)|November 6, 2007
Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysisHans Peter Brunner-La Rocca, Christoph Kaiser, Alain Bernheim, et al.
JAMA|May 10, 2007
Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trialPaul Erne, Andreas W Schoenenberger, Dieter Burckhardt, et al.
Open Heart|June 21, 2019
Drug-eluting stents in large coronary vessels improve both safety and efficacy compared with bare-metal stents in women: a pooled analysis of the BASKET-PROVE I and II trialsLouise Hougesen Bjerking, Kim Wadt Hansen, Rikke Sørensen, et al.
European Heart Journal|November 27, 2008
Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKETMatthias Pfisterer, Hans Peter Brunner-La Rocca, Peter Rickenbacher, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 5, 2003
Prognostic value of abnormal vasoreactivity of epicardial coronary arteries to sympathetic stimulation in patients with normal coronary angiogramsThomas H Schindler, Burkhard Hornig, Peter T Buser, et al.
Journal of the American College of Cardiology|February 19, 2002
Bedside quantification of atherosclerosis severity for cardiovascular risk stratification: a prospective cohort studyPatrick R Hunziker, Christophe Imsand, Dagmar Keller, et al.
Journal of the American College of Cardiology|December 19, 2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stentsMatthias Pfisterer, Hans Peter Brunner-La Rocca, Peter T Buser, et al.
European Journal of Heart Failure|May 10, 2013
N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF)Micha T Maeder, Peter Rickenbacher, Hans Rickli, et al.
Pageof 9

Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
Journal of the American College of Cardiology|February 25, 2012
Coronary artery disease progression late after successful stent implantationMichael J Zellweger, Christoph Kaiser, Raban Jeger, et al.
European Journal of Heart Failure|March 16, 2017
Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)Peter Rickenbacher, Beat A Kaufmann, Micha T Maeder, et al.
Lancet (London, England)|November 6, 2007
Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysisHans Peter Brunner-La Rocca, Christoph Kaiser, Alain Bernheim, et al.
JAMA|May 10, 2007
Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trialPaul Erne, Andreas W Schoenenberger, Dieter Burckhardt, et al.
Open Heart|June 21, 2019
Drug-eluting stents in large coronary vessels improve both safety and efficacy compared with bare-metal stents in women: a pooled analysis of the BASKET-PROVE I and II trialsLouise Hougesen Bjerking, Kim Wadt Hansen, Rikke Sørensen, et al.
European Heart Journal|November 27, 2008
Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKETMatthias Pfisterer, Hans Peter Brunner-La Rocca, Peter Rickenbacher, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 5, 2003
Prognostic value of abnormal vasoreactivity of epicardial coronary arteries to sympathetic stimulation in patients with normal coronary angiogramsThomas H Schindler, Burkhard Hornig, Peter T Buser, et al.
Journal of the American College of Cardiology|February 19, 2002
Bedside quantification of atherosclerosis severity for cardiovascular risk stratification: a prospective cohort studyPatrick R Hunziker, Christophe Imsand, Dagmar Keller, et al.
Journal of the American College of Cardiology|December 19, 2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stentsMatthias Pfisterer, Hans Peter Brunner-La Rocca, Peter T Buser, et al.
European Journal of Heart Failure|May 10, 2013
N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF)Micha T Maeder, Peter Rickenbacher, Hans Rickli, et al.
Pageof 9